Comparative Study of Different Sources of Pertussis Toxin (PT) as Coating Antigens in IgG Anti-PT Enzyme-Linked Immunosorbent Assays

ABSTRACT In an effort to improve the reliability and reproducibility of serological assays for Bordetella pertussis, a collaborative study was conducted to compare four different sources of pertussis toxin (PT) as coating antigens in the immunoglobulin G (IgG) anti-PT enzyme-linked immunosorbent assay (ELISA). Four sources of PT were used as coating antigens in the IgG anti-PT ELISA in four different testing laboratories (labs A to D) to determine whether the different antigen preparations and different laboratories influenced assay results. A panel of 60 sera consisting of deidentified human specimens from previous vaccination trials of healthy adults and infants and clinical specimens from outbreak settings was tested. In the four laboratories, each sample was tested three times with the four PT antigens according to the standard coating optimization and IgG anti-PT ELISA testing procedures used in that laboratory. Differences among the antigens, as well as intra- and interlaboratory variability, were evaluated. Excellent agreement was observed with the test panel results among the four antigens within each laboratory. Concordance correlation coefficient (rc) measurements among the different antigens ranged from 0.99, 0.99 to 1.00, 1.00, and 0.97 to 1.00 for labs A to D, respectively. The comparisons between pairs of laboratories also indicated a high degree of concordance for each PT preparation, with rc measurements between 0.90 and 0.98, 0.93 and 0.99, 0.92 and 0.98, and 0.93 and 0.99 for antigens 1 to 4, respectively. Relatively minor differences in results were observed among laboratories or among antigens, suggesting that the four PT antigens are quite similar and could be considered for acceptance in harmonized immunoassays used for serodiagnosis or vaccine evaluation.

[1]  J. Hockley,et al.  EUVAC.NET collaborative study: evaluation and standardisation of serology for diagnosis of pertussis. , 2011, Journal of immunological methods.

[2]  G. Berbers,et al.  What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[3]  K. Krogfelt,et al.  Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. , 2010, Journal of medical microbiology.

[4]  T. Clark,et al.  Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  C. Deal,et al.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads. , 2010, Vaccine.

[6]  J. Cherry,et al.  Antibody Response Patterns to Bordetella pertussis Antigens in Vaccinated (Primed) and Unvaccinated (Unprimed) Young Children with Pertussis , 2010, Clinical and Vaccine Immunology.

[7]  M. Tondella,et al.  Development and Analytical Validation of an Immunoassay for Quantifying Serum Anti-Pertussis Toxin Antibodies Resulting from Bordetella pertussis Infection , 2009, Clinical and Vaccine Immunology.

[8]  M. Corbel,et al.  Characterization of Reference Materials for Human Antiserum to Pertussis Antigens by an International Collaborative Study , 2008, Clinical and Vaccine Immunology.

[9]  E. Hewlett,et al.  International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007 , 2008, Vaccine.

[10]  R. Pebody,et al.  European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations. , 2008, Vaccine.

[11]  A. Van Rie,et al.  Comparison of Serological and Real-Time PCR Assays To Diagnose Bordetella pertussis Infection in 2007 , 2008, Journal of Clinical Microbiology.

[12]  J. Iskander,et al.  Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  A. Van Rie,et al.  Diagnosis of pertussis: a historical review and recent developments , 2006, Expert review of molecular diagnostics.

[14]  T. Murphy,et al.  Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[15]  K. Edwards.  Overview of Pertussis: Focus on Epidemiology, Sources of Infection, and Long Term Protection After Infant Vaccination , 2005, The Pediatric infectious disease journal.

[16]  K. Edwards,et al.  Establishment of Diagnostic Cutoff Points for Levels of Serum Antibodies to Pertussis Toxin, Filamentous Hemagglutinin, and Fimbriae in Adolescents and Adults in the United States , 2004, Clinical Diagnostic Laboratory Immunology.

[17]  N. Crowcroft,et al.  Laboratory diagnosis of pertussis infections: the role of PCR and serology. , 2004, Journal of medical microbiology.

[18]  S. Nishima,et al.  Seroepidemiologic study on pertussis, diphtheria, and tetanus in the Fukuoka area of southern Japan: seroprevalence among persons 0-80 years old and vaccination program. , 2004, Japanese journal of infectious diseases.

[19]  J. Schellekens,et al.  European Sero-Epidemiology Network: standardisation of the assay results for pertussis. , 2003, Vaccine.

[20]  S. Halperin,et al.  Pertussis of adults and infants. , 2002, The Lancet. Infectious diseases.

[21]  F. Mooi,et al.  Epidemiological Typing of Bordetella pertussis Isolates: Recommendations for a Standard Methodology , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[22]  J. Schellekens,et al.  Specificity and Sensitivity of High Levels of Immunoglobulin G Antibodies against Pertussis Toxin in a Single Serum Sample for Diagnosis of Infection with Bordetella pertussis , 2000, Journal of Clinical Microbiology.

[23]  H. Hallander,et al.  Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. , 1998, Vaccine.

[24]  J. Gornbein,et al.  A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. , 1998, Vaccine.

[25]  G. Reed,et al.  Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens , 1996, Clinical and diagnostic laboratory immunology.

[26]  K. Edwards,et al.  Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. , 1995, Pediatrics.

[27]  G. Siber,et al.  Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. , 1994, The Journal of infectious diseases.

[28]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[29]  N Gochman,et al.  Incorrect least-squares regression coefficients in method-comparison analysis. , 1979, Clinical chemistry.

[30]  Outbreaks of respiratory illness mistakenly attributed to pertussis--New Hampshire, Massachusetts, and Tennessee, 2004-2006. , 2007, MMWR. Morbidity and mortality weekly report.

[31]  Early Release,et al.  Morbidity and Mortality Weekly Report Influenza Vaccination of Health-care Personnel Recommendations of the Healthcare Infection Control Practices Advisory Committee (hicpac) and the Advisory Committee on Immunization Practices (acip) , 2022 .